Takeda Partners for Bowel-Disease DrugBy
Takeda Pharmaceutical has partnered with Finch Therapeutics, a Somerville, Masshachusetts-based privately held microbiome engineering company, to jointly develop a live biotherapeutic product in pre-clinical research for treating inflammatory bowel disease (IBD). The collaboration combines Finch’s discovery platform with Takeda’s experience in drug development for gastrointestinal diseases.
Under the agreement, Takeda will make an upfront payment of $10 million to Finch for the exclusive worldwide rights to develop and commercialize the live biotherapeutic product, FIN-524, and rights to follow-on products in IBD. Finch will be eligible for development, regulatory, and commercial financial milestones as well as tiered royalties on worldwide net sales. Finch and Takeda may elect to extend this collaboration to additional, related indications on similar terms. Further details of the agreement were not disclosed.
Source: Takeda Pharmaceutical